Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03683745
Other study ID # 14698-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 14, 2018
Est. completion date December 30, 2018

Study information

Verified date June 2024
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries. In most instances however, existing case register data generated through national health management information systems or during programmatic activities do not provide an accurate representation of the true burden of IDM NTDs. This study will pilot a cluster randomized screening and confirmation survey to estimate the burden of IDM NTDs characterised by skin conditions associated with long-term disfigurement and disability. These include: leprosy, Buruli ulcer, yaws and lymphoedema and hydrocele resulting from lymphatic filariasis. The survey is being conducted in one county in Liberia. The protocol involves community-level screening by community health volunteers trained to use photo-based visual aids to recognise changes in the skin that broadly indicates patent infection. All suspected cases will be verified in their homes by local and national experts trained in the diagnosis of skin-presenting NTDs. The survey will generate accurate district-level prevalence estimates of leprosy, yaws, Buruli ulcer and lymphatic filariasis-associated lymphoedema and hydrocele and quantify the total costs and cost per case detected. In addition, results from this protocol will be compared with routinely collected case register data, to better understand how health system records reflect the true disease situation on the ground and quantify unmet need.


Description:

Innovative and intensified disease management (IDM) includes a range of different interventions - ranging from medicine to surgery - to relieve the symptoms and consequences of a group of neglected tropical diseases (NTDs) for which effective tools are scarce or where the widespread use of existing tools is limited. The World Health Organisation (WHO) has developed a series of strategies to achieve the control, elimination and eventual eradication of these NTDs, comprising universal access to early diagnosis and prompt treatment, improving active surveillance, integrating passive surveillance into health-service provision, and accelerating efforts towards elimination and eradication by intensifying core interventions. Appropriate targeting of IDM interventions requires accurate epidemiological data on the distribution of these NTDs within endemic countries. In most instances however, existing case register data generated through national health management information systems or during programmatic activities do not provide an accurate representation of the true burden of IDM NTDs. A number of IDM NTDs are characterised by cutaneous manifestations that are associated with long-term disfigurement and disability. These include Buruli ulcer, cutaneous leishmaniasis, leprosy, mycetoma, yaws, onchocerciasis and lymphoedema and hydrocele (resulting from lymphatic filariasis and podoconiosis). These diseases require similar case-detection approaches, presenting opportunities for the development of novel, integrated mapping approaches. Population-based prevalence surveys (PBPS) are the gold standard methodology for obtaining accurate disease estimates when case detection and reporting through the health system is incomplete, and these have been used to provide sub-national estimates of disease distributions for yaws and podoconiosis. For less common outcomes (fewer than 1 case in 1000 individuals) however, standard PBPS rapidly become unfeasible. Given that the expected prevalence range for many of these IDM NTDs in endemic regions lies between as low as 1 in 10,000 for Buruli ulcer and 1-5% for yaws, it is clear that the PBPS approach requires adaptation to achieve the samples sizes needed to generate sufficiently precise prevalence estimates. One alternative to randomly sampling individuals or households is to screen all residents within sampling clusters. House-to-house screening by mobile expert teams would likely yield the highest number of cases, but such a strategy would be expensive and difficult to sustain. As an alternative, trained village volunteers have been used during programmatic activities to effectively detect and refer diseases such as Buruli ulcer and leprosy in a number of countries. Given how difficult it is to diagnose many IDM-NTDs accurately, using community volunteers to perform an exhaustive house-to-house case search would require follow up expert case validation. The success of such an approach would thus rely on high levels of community awareness, coupled with well-trained village volunteers being able to recognise possible conditions, and a highly skilled, mobile case-validation team to confirm all potential cases. Effectively incorporating skill development in IDM-NTD screening among village volunteers could however represent a long-term and sustainable solution to the complex issue of managing these conditions at the community and primary health care level. This study aims to establish the prevalence and distribution of case-management NTDs in the county of Maryland, Liberia using an integrated two-stage cluster-randomised sampling approach, including assessment of the proportion of cases not currently known to the health system. The specific objectives include: 1. To generate regional prevalence estimates of (i) lymphatic filariasis-associated lymphoedema and hydrocele, (ii) yaws, (iii) Buruli ulcer and (iv) leprosy in Maryland, Liberia, including the proportion of cases not currently known to the health system 2. To model the endemicity status of (i) lymphoedema and hydrocele, (ii) yaws, (iii) Buruli ulcer and (iv) leprosy to support the development of targeted, integrated control strategies. 3. To compare case detection rates from active community-based screening and validation with passive case detection reported through routine health system reports and health management information systems. This protocol represents a novel tool for integrated mapping of IDM-NTDs. These conditions are difficult to diagnose and lack effective tools for both case finding and disease management purposes. This strategy may provide a template for cost-effective case identification and management that can be integrated within routine health systems in similar epidemiological settings.


Recruitment information / eligibility

Status Completed
Enrollment 56285
Est. completion date December 30, 2018
Est. primary completion date October 30, 2018
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Adults over 18 must be willing and able to give informed consent for examination, and children over 13 years must be willing and able to give informed assent - An adult (>18 year of age) parent or guardian must be present at the time of the examination who can give informed consent for children <18 years to be examined. Exclusion Criteria: - Individuals for whom no adult parent/guardian is available to provide consent and/or who are unwilling to provide assent/consent for themselves.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Liberia Maryland County Harper Maryland

Sponsors (3)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine AIM Initiative, Ministry of Health, Liberia

Country where clinical trial is conducted

Liberia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Population prevalence of Lymphatic Filariasis Clinical signs of lymphoedema and hydrocele associated with lymphatic filariasis Over a four month period
Primary Population prevalence of Yaws Clinical signs and PCR-confirmed yaws Over a four month period
Primary Population prevalence of Buruli Ulcer Clinical signs and PCR-confirmed Buruli ulcer Over a four month period
Secondary Population prevalence of leprosy Clinical signs of disease and of Grade 2 disability for leprosy Over a four month period
Secondary Population prevalence of BU and yaws in children Clinical signs of Buruli ulcer and yaws in children <15years Over a four month period
Secondary Population prevalence of category 3 Buruli Ulcer Category 3 lesions for Buruli ulcer Over a four month period
See also
  Status Clinical Trial Phase
Completed NCT03302897 - Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers Phase 1
Recruiting NCT05243654 - Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy Phase 2
Completed NCT05091216 - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients N/A
Completed NCT00860717 - The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients N/A
Recruiting NCT06222372 - Novel Interventions and Diagnostic Tests for Leprosy N/A
Terminated NCT03084614 - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting NCT05597280 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy Phase 3
Terminated NCT01751503 - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer N/A
Active, not recruiting NCT03324035 - Treatment of Neuropathic Pain in Leprosy Phase 3
Recruiting NCT02550080 - Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Phase 4
Completed NCT02484469 - Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial N/A
Completed NCT01165840 - Effect of Weight and/or Obesity on Dapsone Drug Concentrations Phase 4
Completed NCT00919542 - Ciclosporin in the Management of New Erythema Nodosum Leprosum Phase 2
Completed NCT05406479 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) Phase 2
Recruiting NCT03807362 - CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum Phase 2
Completed NCT01006759 - Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Phase 1
Completed NCT03662022 - Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Phase 3
Completed NCT01920750 - Leprosy Skin Test Antigens Phase 1 Phase 1
Recruiting NCT06416033 - Serum Irisin Level In Leprosy Patients
Not yet recruiting NCT03947437 - Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients Phase 1/Phase 2